MS18.04 Retreatment With Platinum and Etoposide and Treatment Beyond Second Line

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.164
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Characteristics and Outcomes of Patients With Relapsed Follicular Lymphoma Following Retreatment With Second-Line Rituximab-Containing Chemotherapy

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Treatment of Metastatic Germ Cell Tumors With Etoposide and Cisplatin as First Line Chemotherapy

Japanese Journal of Urology
Urology
2002English

Prognostic Factors of Second and Third Line Chemotherapy Using 5-Fu With Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2011English

Second-Line Treatment of Ovarian Cancer

Oncologist
Cancer ResearchMedicineOncology
2000English

Treatment With Cisplatin and Etoposide Chemotherapy in Patient With Metastatic Breast Cancer

Journal of Breast Disease
2017English

Second-Line Treatment Options in Hepatocellular Carcinoma

Drugs in Context
Molecular MedicinePharmacology
2019English

Second-Line Treatment for Renal Cell Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy